Delisting riskPopularity #4,249
FibroBiologics (FBLG)
Develops allogeneic fibroblast therapies for diabetic foot ulcers and other chronic diseases.
$1.34
vs last close0.00 (0.00%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 4.28% | 284.9K shares | |
|---|---|---|---|
| 16 holders · as of Jun 30, 2026 | |||
| Insiders | 9.19% | 612.0K shares | |
| 4 holders · as of Sep 15, 2026 | |||
| Strategic holders | 11.10% | 739.0K shares | |
| 1 holder · as of Aug 14, 2026 | |||
| Other | 75.43% | 5.02M shares | |
| remainder | |||
6.66M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (6.66M in the company's Sep 23, 2026 report, 2.10M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
16 holders · 284.9K shares · 4 new positions · 8 increased · 4 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Cascade Financial Partners, LLC | 108.8K | 1.63% | +92.4K | Aug 4, 2026 |
| Fund Evaluation Group, LLC | 51.8K | 0.78% | 0 | Aug 7, 2026 |
| Geode Capital Management, LLC | 30.3K | 0.46% | +690 | Aug 12, 2026 |
| Vanguard Capital Management LLC | 27.8K | 0.42% | −39.9K | Aug 13, 2026 |
| Qube Research & Technologies Ltd | 24.3K | 0.37% | +24.3Knew | Aug 14, 2026 |
| BlackRock, Inc. | 18.2K | 0.27% | −6.4K | Aug 7, 2026 |
| Barclays PLC | 7.2K | 0.11% | +7.2Knew | Aug 14, 2026 |
| Vanguard Fiduciary Trust Co | 6.4K | 0.10% | 0 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Pete O'Heeron | 18.20% | 13G | Feb 12, 2025 | |
| Armistice Capital, LLC | 9.99% | 739.0K | 13G | Aug 14, 2026 |
| Hamid Khoja | 7.50% | 630.0K | 13D | Sep 17, 2026 |
| Mike Newlin | 5.58% | 13G | Jun 6, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 4, 2026 | Hamid Khojaofficer: Chief Scientific Officer | Purchase | 30,000 | $0.3800 | 61,250 |
| Mar 2, 2026 | Pete O'Heerondirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 17,428 | $0.3530 | 5,924,075 |
| Mar 3, 2026 | Pete O'Heerondirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 18,200 | $0.4051 | 5,942,275 |
| Mar 4, 2026 | Pete O'Heerondirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 15,872 | $0.3784 | 5,958,147 |
| Mar 2, 2026 | Jason Davisofficer: Chief Financial Officer | Purchase | 70,000 | $0.4139 | 70,000 |
| Feb 27, 2026 | Ruben A. Garciaofficer: General Counsel | Purchase | 40,000 | $0.3264 | 180,000 |
| Dec 11, 2025 | Ruben A. Garciaofficer: General Counsel | Purchase | 140,000 | $0.3400 | 140,000 |
House and Senate disclosures
Not reported.